Zocor Legal News Articles & Interviews

Washington, DC Thirteen years after high-dose Zocor was approved by the US Food and Drug Administration (FDA) as a drug whose benefits outweighed its risks, the health regulator has slapped new restrictions on the drug over concern for the onset of myopathy.

Silver Spring, MD The US Food and Drug Administration (FDA) issued a warning about the potential for an increased risk of muscle injury when patients use 80 mg of Zocor (simvastatin). The muscle injury, known as myopathy, is a side effect of all statins; however, the warning highlights the increased risk of developing this injury when patients use higher doses of Zocor. The warning includes an increased risk of rhabdomyolysis, a serious form of myopathy that can lead to kidney damage, kidney failure and death.